Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Review ArticleTeaching Case Studies

Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of 68Ga/177Lu-DOTATATE with Improvement of Vision

Rahul V. Parghane and Sandip Basu
Journal of Nuclear Medicine Technology June 2019, 47 (2) 171-172; DOI: https://doi.org/10.2967/jnmt.118.217455
Rahul V. Parghane
Radiation Medicine Centre, Tata Memorial Hospital Annexe, Mumbai, India; and Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandip Basu
Radiation Medicine Centre, Tata Memorial Hospital Annexe, Mumbai, India; and Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A gratifying clinical response obtained in the setting of bilateral orbital metastases from renal neuroendocrine tumor is reported. Methods: A 53-y-old man diagnosed with renal neuroendocrine tumor (MIB1 index, 4%), with symptoms of skeletal and abdominal pain, proptosis, and a decrease in vision of the left eye, was found to harbor bilateral orbital soft-tissue lesions on 68Ga-DOTATATE PET/CT and MRI in addition to widespread metastatic skeletal lesions and metastatic lymph nodal disease. Despite radiotherapy to the left eye (20 Gy) and long-acting octreotide therapy for 18 mo, his symptoms worsened, with an increase in serum chromogranin A level, and he was considered for 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT). Results: There was a significant improvement in skeletal pain, proptosis, and vision after 4 cycles of PRRT (cumulative dose of 22.2 GBq), stable disease on scanning, and a decrease in serum chromogranin A (from 150 to 36.39 ng/mL), with progression-free survival at 18 mo. Conclusion: PRRT through theranostic application of 68Ga/177Lu-DOTATATE was thus helpful in this uncommon clinical setting.

  • renal neuroendocrine tumor
  • orbital metastases
  • 68Ga-DOTATATE
  • 177Lu-DOTATATE
  • PRRT

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms with differing biologic behavior and response to treatment. Neuroendocrine cells are usually not found within normal renal parenchyma, resulting in a relatively rare incidence of primary renal NET, with a debatable pathogenesis. Different theories have been put forth to support the origin: primitive totipotential stem cells that subsequently differentiate in a neuroendocrine direction, metastasis from an occult primary tumor site to the kidney, or activation of aberrant gene sequences in a totipotential stem cell line that differentiates into aberrant NET cells (1,2).

CASE REPORT

A 53-y-old man diagnosed with renal NET (MIB1 index, 4%) presented with skeletal pain all over the body, abdominal pain, proptosis, and a decrease in the vision of the left eye, 1 y after right nephrectomy. The imaging findings are shown in Figure 1. 68Ga-DOTATATE PET/CT demonstrated enhanced tracer uptake in widespread metastatic skeletal lesions; cervical, mediastinal, and abdominopelvic metastatic lymph nodal disease; and bilateral orbital soft-tissue lesions. MRI of the head showed oval to rounded T2-hyperintense and T1-hypointense lesions with moderate homogeneous enhancement involving the left lateral rectus, left inferior oblique, right lateral rectus, and right inferior oblique muscles in an intraconal location, with compression of the left optic nerve. He received local radiotherapy to the left eye (20 Gy) and systemic octreotide (for 18 mo); however, the symptoms worsened even on these therapies, and there was an increase in the serum chromogranin A level. Thus, he was considered for 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in view of high uptake on 68Ga-DOTATATE PET/CT. There was significant improvement in skeletal pain, proptosis, and vision (resulting in a better quality of life) after 4 cycles of PRRT with a cumulative dose of 22.2 GBq, stabilization of disease on scanning, and a decrease in the serum chromogranin A level (from 150 to 36.39 ng/mL), with progression-free survival at 18 mo.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

(A) 68Ga-DOTATATE PET/CT showing increased tracer uptake in widespread metastatic skeletal lesions; in cervical, mediastinal, abdominopelvic lymph nodes; and bilaterally in orbital soft-tissue lesions. (B) MRI of head showing oval to rounded T2-hyperintense and T1-hypointense lesions with moderate homogeneous enhancement involving left lateral rectus, left inferior oblique, right lateral rectus, and right inferior oblique muscles in intraconal locations with compression of left optic nerve, along with abnormal tracer uptake on fused PET/MRI. (C) Scan at 24 h after PRRT demonstrating adequate tracer uptake in multiple metastatic lesions.

DISCUSSION

The clinical course of renal NET is unpredictable: largely believed to have an indolent course (well-differentiated type), its current recommended management includes radical nephrectomy with surveillance. For any metastatic disease, medical management with or without a surgical approach is considered (1). Because of its asymptomatic nature, renal NET can present with metastatic disease (∼45.6% of reported cases), the common sites being lymph nodes and liver (2).

Orbital metastases from NET are rare and typically occur through hematogenous spread by the carotid and ophthalmic arteries. The management options include excision, orbital exenteration, radiotherapy, hormonal therapy, and chemotherapy. However, there is no definitive consensus approach on management, with a loss of vision after exenteration, a high chance of recurrence after surgical excision, and a mixed response after radiotherapy (3). The overall reported survival for metastatic orbital NET is 72% at 5 y and 38% at 10 y (4); preserving vision and maintaining a good quality of life are fundamentally important in the management of these patients. In such cases, PRRT is a potential treatment option for disseminated lesions, is well tolerated and safe, and can be effective, resulting in improvement of vision along with a better quality of life.

CONCLUSION

PRRT through theranostic application of 68Ga/177Lu-DOTATATE was helpful in this uncommon clinical setting.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Aug. 23, 2018.

REFERENCES

  1. 1.↵
    1. Teegavarapu PS,
    2. Rao P,
    3. Matrana M,
    4. et al
    . Neuroendocrine tumors of the kidney: a single institution experience. Clin Genitourin Cancer. 2014;12:422–427.
    OpenUrl
  2. 2.↵
    1. Lane BR,
    2. Chery F,
    3. Jour G,
    4. et al
    . Renal neuroendocrine tumours: a clinicopathological study. BJU Int. 2007;100:1030–1035.
    OpenUrlPubMed
  3. 3.↵
    1. Peixoto RD,
    2. Lim HJ,
    3. Cheung WY
    . Neuroendocrine tumor metastatic to the orbit treated with radiotherapy. World J Gastrointest Oncol. 2013;5:177–180.
    OpenUrl
  4. 4.↵
    1. Mehta JS,
    2. Abou-Rayyah Y,
    3. Rose GE
    . Orbital carcinoid metastases. Ophthalmology. 2006;113:466–472.
    OpenUrlCrossRefPubMed
  • Received for publication July 9, 2018.
  • Accepted for publication August 9, 2018.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 47 (2)
Journal of Nuclear Medicine Technology
Vol. 47, Issue 2
June 1, 2019
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of 68Ga/177Lu-DOTATATE with Improvement of Vision
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of 68Ga/177Lu-DOTATATE with Improvement of Vision
Rahul V. Parghane, Sandip Basu
Journal of Nuclear Medicine Technology Jun 2019, 47 (2) 171-172; DOI: 10.2967/jnmt.118.217455

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of 68Ga/177Lu-DOTATATE with Improvement of Vision
Rahul V. Parghane, Sandip Basu
Journal of Nuclear Medicine Technology Jun 2019, 47 (2) 171-172; DOI: 10.2967/jnmt.118.217455
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • High-Sensitivity Troponin Elevation in a Young Woman with Typical Chest Pain: The Heart of the Matter
  • Pulmonary Adenocarcinoma Revealed by Parathyroid Scintigraphy: An Incidental Case to Remember
  • Prominent Right Ventricular Tracer Uptake: A Harbinger of Multivessel Coronary Artery Disease
Show more Teaching Case Studies

Similar Articles

Keywords

  • Renal Neuroendocrine Tumor
  • orbital metastases
  • 68Ga-DOTATATE
  • 177Lu-DOTATATE
  • PRRT
SNMMI

© 2025 SNMMI

Powered by HighWire